BBI Solutions Acquires BioTeZ Berlin-Buch

BBI Solutions, an independent provider of immune-diagnostic reagents and contract services, has announced on Jan. 4, 2022 that it has completed the acquisition of BioTeZ Berlin-Buch—a Germany-based manufacturer of reagents and finished tests for the in-vitro diagnostics market.

Through the acquisition, which also includes Steffens Biotechnische Analysen, BBI Solutions will increase its capabilities and will enhance its portfolio and position as a ‘complete’ immunoassay reagent supplier. Adding to BBI Solutions’ existing portfolio will be the BioTeZ’s Streptavidin-based portfolio, as well as immunoassay development services that will complement the company’s existing service offering.

“This latest acquisition of BioTeZ and Steffens-Biotec further enhances our portfolio and positions BBI as a leading immunoassay reagent supplier,” said Mario Gualano, CEO of BBI Group in the press release. “It enables us to provide additional products and services in the fight against the COVID pandemic. The combined research and development capability will provide customers of both BioTeZ and BBI with new, innovative products and a broader portfolio for greater choice.”

“We are very proud to become part of the BBI family and to be able to reach many more customers worldwide,” added Uwe Ahnert, CEO of BioTeZ, in the press release. “In doing so, we will be able to support them in the production and development of innovative diagnostics.”

Source: BBI Solutions